Proteomics-driven insights for pharmaceutical development Publication highlights April 2026

Proteomics-driven insights for pharmaceutical development Publication highlights April 2026 Escalating costs and increasing demands from regulatory authorities for a more precision medicine-based approach to drug development are substantial challenges for the pharmaceutical industry. Olink’s PEA technology is increasingly used to identify new drug targets and analyze samples from clinical trials to stratify patient populations, predict responses, and provide insights into the biology of disease and drug modes of action. Here we highlight some recent outstanding studies that illustrate the key role of protein biomarker research in the discovery and development of new therapies. https://olink.com/blog/proteomics-driven-insights-for-pharmaceutical-development?utm_campaign=26-01-global-core-genomics-virtual-journal-club&utm_medium=email&_hsenc=p2ANqtz-987lCEnxWVyVHTyXD3YOu4QWS9GrHGff0H8QV_4FDYDPlWsNoryP09Cfzz-gEmpKqjjrI2X87PaP3qnmzn9wSH29QsaQ&_hsmi=416418473&utm_content=cta-1&utm_source=olink